Prevalence of GVHD in Patients With B-Cell Malignancies Receiving Allogeneic CAR T-Cells
In a meta-analysis presented at the 2022 American Society of Clinical Oncology Annual Meeting, researchers evaluated allogeneic chimeric antigen receptor (CAR) T-cell therapy in...
GVHD Prophylaxis Well-Tolerated in Patients With PTCL Undergoing Transplant
According to research presented at the 2022 American Society of Clinical Oncology Annual Meeting, graft-versus-host disease (GVHD) prophylaxis with post-transplant cyclophosphamide—as well as mycophenolate...
GVHD Is Less Common in Hispanic Patients With MPN Than Non-Hispanic White Patients
Hispanic patients had a significantly lower cumulative incidence of chronic graft-versus-host disease (GVHD) than non-Hispanic White patients in a retrospective analysis of those with...
No GVHD Reported in First-in-Human Trial of ADI-001 CAR-T for Relapsed/Refractory Advanced B-Cell Lymphoma
The first-in-human, phase I clinical trial of ADI-001, an allogeneic gamma delta chimeric antigen receptor (CAR) T-cell therapy, in relapsed/refractory advanced B-cell lymphoma established...
Literature Review Assesses Use of Ruxolitinib in Chronic Steroid-Refractory GVHD
A study presented at the 2022 American Society of Clinical Oncology Annual Meeting reported on results of a literature review compiling outcomes of ruxolitinib...
Chronic GVHD Incidence Significantly Lower in Patients With HLA-Matched Donors Than Haploidentical Donors
Patients who received an allogeneic hematopoietic stem cell transplant (HSCT) from matched related donors (MRD) or matched unrelated donors (MUD) had a significantly lower...
CAR T-Cell Therapy Appeared Safe, With No Signs of GVHD in Patients With T-Cell...
A study presented at the 2022 American Society of Clinical Oncology Annual Meeting found that an autologous CD7 chimeric antigen receptor (CAR) T-cell therapy...
Mismatched Donor Transplantation Associated With Minimal GVHD in Cutaneous T-Cell Lymphoma
A retrospective study found that partially mismatched blood or marrow transplantation with post-transplantation cyclophosphamide resulted in minimal graft-versus-host disease (GVHD) and improved survival in...
